Anhui honochem Co.,Ltd is committed to serving the fields of drug research and development, scientific research, and material manufacturing. The company has always focused on the design and synthesis of drug molecular blocks; Process development, pilot production, commercial production, and sales of key intermediates. The company has a research and development center, a pilot plant, a production base, and a stable cooperative factory. The sales center is located in Ma'anshan. At the same time, we closely cooperate with major universities such as Beijing University of Technology, Anhui University of Technology, China University of Pharmacy, and Nanjing University of Technology, leveraging the technological advantages of universities to accelerate technological innovation.
On August 5th, the official website of the National Medical Products Administration (NMPA) of China announced that the anti PD-1 antibody drug, Paprilimab (AK105), jointly declared by Kangfang Biotechnology and Zhengda Tianqing, has been approved. According to public information, the indications for the approval of piazeprizumab this time are: for the treatment of recurrent or refractory classic cases that have undergone at least second-line systemic chemotherapy
Recently (August 9, 2021), according to CDE announcement, BBM-H901 injection from Xinzhi Pharmaceutical Technology has been approved for clinical use in type B hemophilia.
Type B hemophilia is a type of hemophilia caused by a lack of coagulation factor IX, accounting for approximately 15% of the total number of hemophiliacs. The most common treatment method is intravenous injection of concentrated factor
On August 8, 2021, Rongchang Biotechnology (09995. HK) reached a global exclusive licensing agreement with internationally renowned biopharmaceutical company Seagen Inc. (SGEN) to develop and commercialize its ADC new drug, vidiximab.
Although the Federal Trade Commission (FTC) of the United States has sued to block this transaction, and the European Union is also launching an antitrust investigation, the acquisition case has still been completed.
Our scientifically driven, customer-oriented, flexible, and people-oriented corporate culture enables us to provide comprehensive and fast exclusive services to the global biopharmaceutical industry, accelerating the process of new drug research and development. Welcome partners with a healthy dream and shared values to join us!